Implications for employers: - Direct purchase from a pharmaceutical company of GLP-1 medications effective in obesity treatment at this point remains cost-prohibitive for most plan members with obesity who do not have coverage in their employer-sponsored plans
In 2024, a large study of over 160,000 individuals showed that GLP-1RAs are associated with a 195% higher risk of major depression, 108% increased risk for anxiety, and 106% elevated risk for suicidal behavior
Finally, calculate the enzyme activity using the formula provided in the kit instructions, considering the sample volume, reaction time, and phosphate concentration
(4) increased hepatic and renal urea cycle intermediates suggesting hypercatabolism and upregulation of the urea cycle independent of impaired renal clearance of nitrogenous waste
We need to get more doctors trained in the matter to properly guide patients